Endomag Secures £15 Million ($20 Million) in Series D Funding
11/30/20, 10:34 AM
Location
cambridgeMoney raised
£15 million
Round Type
series d
Endomag, a breast cancer market leader and one of the UK’s fastest growing private technology businesses1, has secured £15m (~$20m) in Series D funding. These funds are earmarked for expanding access to new advanced techniques enabled by its products, such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB). The funds will also be used to scale its product offering, market reach and employees.
Company Info
Location
cambridge, maryland, united states
Additional Info
Endomag is a global technology company that believes everyone deserves a better standard of cancer care. Many of the world’s leading physicians and hospitals use the company’s technologies to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is.